Already offering the only non-invasive treatment for SMA in liquid form, Roche’s Evrysdi now comes as a tablet.

Simplified storage and administration of new tablet formulation may provide greater freedom and independence for people with ...

The development of oral dosage forms for clinical trials presents a unique set of challenges, particularly in early phases of ...

The European Commission (EC) has approved a label extension for Roche’s Evrysdi (risdiplam) to include a tablet for people living with SMA.

The tablet formulation can either be swallowed whole ... Genentech’s chief medical officer and head of Global Product Development, said: “The Evrysdi tablet combines established efficacy ...

Frontage Laboratories, Inc. hosted a grand opening event to unveil its newest Contract Research, Development, and ...

"Prior 28-day Phase 1 data demonstrated encouraging tolerability with the tablet ... with the development of oral VK2735, Viking is also advancing a subcutaneous formulation of VK2735 through ...

Award recognises advances in pharmaceutical excipient technology improving tablet formulationJapanese firm Asahi Kasei has ...

Tablets are the most used oral dose ... Coating consistency is required for the successful development and production of such formulations. The Relative Standard Deviation (RSD) measures coating ...

Under the terms of the Agreement, OPKO will supply its proprietary long-acting GLP-2 peptide and certain Oxyntomodulin (OXM) analogs for the development of oral tablet formulations using Entera ...

13-Week Study to Evaluate the Safety and Efficacy of Oral VK2735 Dosed Once Daily SAN DIEGO, Jan. 8, 2025 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage ...